TRAX director granted options and RSUs
First Tracks Biotherapeutics director John A. Orwin received new equity awards.
Rhea-AI Filing Summary
First Tracks Biotherapeutics director John A. Orwin received new equity awards. He was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, vesting in 12 equal monthly installments starting on June 12, 2026, as long as he continues serving the company.
Orwin also received 15,000 restricted stock units, each representing one share of common stock for no cash cost upon settlement. These RSUs vest 100% on the date of the company’s 2027 annual shareholder meeting, subject to continued service. A footnote notes he also holds other options covering up to 55,181 shares that vest under their existing terms.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 57,000 shares
Grant/Award
2 txns
Insider
Orwin John A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 15,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) | 42,000 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Unit — 15,000 contracts (Direct);
Stock Option (right to buy) — 42,000 contracts (Direct)
Footnotes (4)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- F2. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- F3. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- F4. In addition to the options to purchase a total of 42,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 55,181 shares of common stock, which options vest according to their terms.
Key Figures
Option grant size: 42,000 shares
Option exercise price: $17.81/share
RSU grant size: 15,000 units
+3 more
6 metrics
Option grant size
42,000 shares
Stock options to buy common stock granted to John A. Orwin
Option exercise price
$17.81/share
Exercise price for newly granted stock options
RSU grant size
15,000 units
Restricted stock units granted, each for 1 share at settlement
RSU vesting
100% at 2027 meeting
RSUs vest on date of 2027 annual shareholder meeting
Option vesting schedule
1/12 monthly from Jun 12, 2026
Monthly vesting for 42,000-share option grant
Additional existing options
55,181 shares
Other options already held by Orwin, vesting per their terms
Key Terms
Restricted Stock Unit, contingent right, vests as to 100% of the total RSUs, stock option vests as to 1/12, +1 more
5 terms
Restricted Stock Unit financial
"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
contingent right financial
"represents a contingent right to receive 1 share of the Issuer's Common Stock"
vests as to 100% of the total RSUs financial
"The RSUs vests as to 100% of the total RSUs on the date"
stock option vests as to 1/12 financial
"The stock option vests as to 1/12 of the total shares monthly"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did TRAX director John A. Orwin report on this Form 4?
John A. Orwin reported receiving equity compensation awards, not open-market trades. He was granted stock options for 42,000 shares and 15,000 restricted stock units, each tied to continued service and specific vesting schedules described in the filing’s footnotes.
How many stock options did John A. Orwin receive from First Tracks Biotherapeutics (TRAX)?
Orwin received stock options covering 42,000 shares of First Tracks Biotherapeutics common stock. These options vest monthly in 12 equal installments beginning June 12, 2026, provided he continues to serve the company on each vesting date, according to the Form 4 footnotes.
What are the terms of John A. Orwin’s RSU grant from First Tracks Biotherapeutics (TRAX)?
Orwin received 15,000 restricted stock units, each representing one share for no cash consideration at settlement. All RSUs vest on the date of the company’s 2027 annual shareholder meeting, contingent on his continued service through that vesting date, as specified in the filing.
What is the exercise price and vesting schedule for TRAX stock options granted to John A. Orwin?
The granted stock options have an exercise price of $17.81 per share. They vest as to one-twelfth of the total option shares each month starting June 12, 2026, continuing until fully vested, subject to Orwin’s continued service with the company.
Does John A. Orwin hold any additional TRAX stock options beyond this new grant?
Yes. A footnote states that, in addition to the newly granted options for 42,000 shares, Orwin already holds other options to purchase up to an aggregate of 55,181 shares of common stock. Those prior options continue to vest according to their existing terms.
Are John A. Orwin’s new TRAX awards open-market purchases or compensation grants?
They are compensation-related grants, not market purchases. Both the 42,000 stock options and 15,000 restricted stock units are coded as awards, with a transaction code indicating grant or other acquisition, and a per-share transaction price of $0.00 at grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
